Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Extension

20 Oct 2005 07:00

Angle PLC20 October 2005 For Immediate Release 20 October 2005 ANGLE plc CONTRACT EXTENSION ANGLE plc the venture management and consulting company specialising in thecommercialisation of technology is pleased to announce that The Fairfax CountyEconomic Development Authority ("FCEDA") has extended its contract with ANGLETechnology Group US ('ANGLE Technology') through until June 2007. ANGLETechnology, headquartered in Virginia and formed in 1999, is the US technologydivision of ANGLE plc. The FCEDA promotes Fairfax County, Virginia, as aworld-class centre of commerce and trade and the technology hub of the eastcoast of the United States. The contract extension value is $0.47 million taking the total contract valuesince commencement in October 2001 to $1.92 million. Under the terms of thecontract, ANGLE Technology is to further develop, manage and provide fullon-going support to the BioAccelerator of Fairfax County, a business incubationprogram set-up in 2002 to develop early-stage biotechnology, biomedical andbioinformatics companies. The FCEDA created the BioAccelerator of Fairfax County to serve as a catalystfor the development of the bioscience industry in Northern Virginia. The role ofANGLE Technology ranges from business plan review, sales and marketing advice,and business mentoring, to recruitment activities and assistance with financingfor companies in the BioAccelerator. These companies represent convergingtechnologies that include bioscience, nanotechnology, environmental sciences,medical devices and software for biomedical research and healthcare. The ANGLE team also actively supports FCEDA marketing investment ininternational life science companies. Support for these companies focuses on theestablishment of US business operations and the development of targeted USmarketing activities. Andrew Newland, Chief Executive of ANGLE said: "Fairfax County is leading location in the United States for biomedicaltechnology. We are delighted that this important contract has again beenextended. In addition to its financial value, our work on the BioAcceleratorprovides us with a pipeline of opportunities for our expanding ventures businessin the Mid-Atlantic region of the US." For further information, please contact: ANGLE plc Tel: +44 (0)1483 295830Andrew Newland, Chief Executive Ian Griffiths, Finance Director Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors ANGLE plc - founded in 1994, ANGLE is an international venture management andconsulting company focusing on the commercialisation of technology and thedevelopment of technology-based industry. ANGLE creates, develops and advisestechnology businesses on its own behalf and for its clients. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.